Cedar Mountain Advisors
JAZZ icon

Cedar Mountain Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cedar Mountain Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.6K Hold
115
– – ﹤0.01% 251
2026
Q2 		$27.7K Hold
115
– – ﹤0.01% 268
2026
Q1 		$21.7K Buy
+115
New +$20.1K ﹤0.01% 279

Other funds holding JAZZ

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Cedar Mountain Advisors's JAZZ Position: Q3 2026 in Review

Cedar Mountain Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q3 2026 at 115 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #251.

Cedar Mountain Advisors first reported a position in JAZZ in Q1 2026 and has held it in 3 quarters since. The position peaked at $27.7K in Q2 2026. 538 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Cedar Mountain Advisors held 115 shares of Jazz Pharmaceuticals worth $26.6K as of Q3 2026.
  • Cedar Mountain Advisors left its Jazz Pharmaceuticals share count unchanged in Q3 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #251 holding.
  • Cedar Mountain Advisors first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Cedar Mountain Advisors's Jazz Pharmaceuticals position peaked at $27.7K in Q2 2026.
  • 538 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.